56
Participants
Start Date
August 30, 2023
Primary Completion Date
March 23, 2035
Study Completion Date
March 23, 2035
AAV5-hFIXco-Padua
Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
11-31 Cliniques Universitaires Saint-Luc, Brussels
12-32 Rigshospitalet, Copenhagen
11-30 Universitair Ziekenhuis Leuven, Leuven
15-42 Vivantes Klinikum im Friedrichshain - Landsberger Allee, Berlin
10-16 University of North Carolina at Chapel Hill, Chapel Hill
10-19 University of South Florida, Tampa
10-20 Vanderbilt University Medical Center, Nashville
10-10 University of Michigan Medical Center, Ann Arbor
10-14 Arkansas Children's Hospital - Pharmacology, Little Rock
10-28 University of Texas Health Science Center, Houston
10-25 University of Colorado Denver, Aurora
10-26 University of Utah, Salt Lake City
10-15 Phoenix Childrens Hospital, Phoenix
10-22 Orthopaedic Institute for Children, Los Angeles
10-21 Children's Hospital of Los Angeles, Los Angeles
10-12 University of California, San Diego (UCSD), San Diego
10-63 UC Davis Medical Center, Sacramento
10-18 Oregon Health & Science University, Portland
10-62 Washington Institute for Coagulation, Seattle
19-56 St. James Hospital, Dublin
13-33 Amsterdam Universitair Medische Centra (UMC), Amsterdam-Zuidoost
13-35 University Medical Center Groningen, Groningen
13-34 Erasmus University Medical Center, Rotterdam
13-36 Universitair Medisch Centrum Utrecht, Utrecht
16-43 Skane University Hospital, Malmo
18-52 Barts Health NHS Trust, London
18-54 Addenbrooke's Hospital, Cambridge
18-53 University Hospital Southampton NHS Foundation Trust, Southampton
Lead Sponsor
CSL Behring
INDUSTRY